Steven R Goldsmith

Summary

Publications

  1. doi request reprint Treatment options for hyponatremia in heart failure
    Steven R Goldsmith
    Cardiology Division, Hennepin County Medical Center, 701 Park Avenue, Minneapolis, MN 55415, USA
    Heart Fail Rev 14:65-73. 2009
  2. doi request reprint The sympathorenal axis in hypertension and heart failure
    Steven R Goldsmith
    Cardiology Division, Hennepin County Medical Center and University of Minnesota, Minneapolis, MN, USA
    J Card Fail 16:369-73. 2010
  3. ncbi request reprint Treating hyponatremia in heart failure
    Steven R Goldsmith
    Cardiology Division, Hennepin County Medical Center, MN 55415, USA
    Curr Cardiol Rep 8:204-10. 2006
  4. ncbi request reprint The role of vasopressin in congestive heart failure
    Steven R Goldsmith
    Division of Cardiology, Hennepin County Medical Center, Minneapolis, MN 55415, USA
    Cleve Clin J Med 73:S19-23. 2006
  5. ncbi request reprint Is there a cardiovascular rationale for the use of combined vasopressin V1a/V2 receptor antagonists?
    Steven R Goldsmith
    Division of Cardiology, Hennepin County Medical Center, Minneapolis, Minnesota 55415, USA
    Am J Med 119:S93-6. 2006
  6. ncbi request reprint Vasopressin receptor antagonists: mechanisms of action and potential effects in heart failure
    Steven R Goldsmith
    Division of Cardiology, Hennepin County Medical Center, Minneapolis, MN 55415, USA
    Cleve Clin J Med 73:S20-3; discussion S30-3. 2006
  7. ncbi request reprint Vasopressin antagonism in heart failure
    Steven R Goldsmith
    Hennepin County Medical Center, University of Minnesota, Minneapolis, Minnesota, USA
    J Am Coll Cardiol 46:1785-91. 2005
  8. doi request reprint Treatment options for hyponatremia in heart failure
    Steven R Goldsmith
    From the Hennepin County Medical Center, Minneapolis, Minnesota, and the University of Minnesota, Minneapolis, MN 55415, USA
    Congest Heart Fail 16:S15-8. 2010
  9. ncbi request reprint Current treatments and novel pharmacologic treatments for hyponatremia in congestive heart failure
    Steven R Goldsmith
    University of Minnesota Medical School, Minneapolis, Minnesota 55415, USA
    Am J Cardiol 95:14B-23B. 2005
  10. doi request reprint Congestion as a therapeutic target in acute heart failure syndromes
    Steven R Goldsmith
    Cardiology Division, Hennepin County Medical Center and University of Minnesota, Minneapolis, MN 55415, USA
    Prog Cardiovasc Dis 52:383-92. 2010

Detail Information

Publications20

  1. doi request reprint Treatment options for hyponatremia in heart failure
    Steven R Goldsmith
    Cardiology Division, Hennepin County Medical Center, 701 Park Avenue, Minneapolis, MN 55415, USA
    Heart Fail Rev 14:65-73. 2009
    ..Clinical trials in patients with hyponatremia and CHF using both selective and nonselective vasopressin antagonists have demonstrated the effectiveness of these agents in correcting this common electrolyte abnormality...
  2. doi request reprint The sympathorenal axis in hypertension and heart failure
    Steven R Goldsmith
    Cardiology Division, Hennepin County Medical Center and University of Minnesota, Minneapolis, MN, USA
    J Card Fail 16:369-73. 2010
    ..Should their early promise be borne out in controlled studies, the "sympathorenal axis" will have been proven to be a key element in the pathophysiology of these 2 very common, and dangerous, conditions...
  3. ncbi request reprint Treating hyponatremia in heart failure
    Steven R Goldsmith
    Cardiology Division, Hennepin County Medical Center, MN 55415, USA
    Curr Cardiol Rep 8:204-10. 2006
    ..Studies in experimental CHF as well as preliminary clinical trials with selective and nonselective V2 antagonists have been encouraging, suggesting that these agents may hold promise for treatment of hyponatremia in CHF...
  4. ncbi request reprint The role of vasopressin in congestive heart failure
    Steven R Goldsmith
    Division of Cardiology, Hennepin County Medical Center, Minneapolis, MN 55415, USA
    Cleve Clin J Med 73:S19-23. 2006
    ..of arginine vasopressin (AVP) has the potential for deleterious effects on various physiologic processes in CHF Inhibition of AVP through vasopressin receptor antagonist therapy is a potentially beneficial new therapeutic approach to CHF..
  5. ncbi request reprint Is there a cardiovascular rationale for the use of combined vasopressin V1a/V2 receptor antagonists?
    Steven R Goldsmith
    Division of Cardiology, Hennepin County Medical Center, Minneapolis, Minnesota 55415, USA
    Am J Med 119:S93-6. 2006
    ..Therefore, a strong rationale exists for the use of combined vasopressin antagonists in patients with heart failure, particularly if the agents are used on a chronic basis...
  6. ncbi request reprint Vasopressin receptor antagonists: mechanisms of action and potential effects in heart failure
    Steven R Goldsmith
    Division of Cardiology, Hennepin County Medical Center, Minneapolis, MN 55415, USA
    Cleve Clin J Med 73:S20-3; discussion S30-3. 2006
    ..Combined V1a and V2 receptor antagonism could potentially prove advantageous as a therapy for heart failure by acting synergistically to facilitate diuresis and improve hemodynamics...
  7. ncbi request reprint Vasopressin antagonism in heart failure
    Steven R Goldsmith
    Hennepin County Medical Center, University of Minnesota, Minneapolis, Minnesota, USA
    J Am Coll Cardiol 46:1785-91. 2005
    ....
  8. doi request reprint Treatment options for hyponatremia in heart failure
    Steven R Goldsmith
    From the Hennepin County Medical Center, Minneapolis, Minnesota, and the University of Minnesota, Minneapolis, MN 55415, USA
    Congest Heart Fail 16:S15-8. 2010
    ....
  9. ncbi request reprint Current treatments and novel pharmacologic treatments for hyponatremia in congestive heart failure
    Steven R Goldsmith
    University of Minnesota Medical School, Minneapolis, Minnesota 55415, USA
    Am J Cardiol 95:14B-23B. 2005
    ....
  10. doi request reprint Congestion as a therapeutic target in acute heart failure syndromes
    Steven R Goldsmith
    Cardiology Division, Hennepin County Medical Center and University of Minnesota, Minneapolis, MN 55415, USA
    Prog Cardiovasc Dis 52:383-92. 2010
    ..The review concludes with recommendations for possible new strategies and specific investigations designed to benefit from the lessons learned from both the recent successful trials and the more numerous failures...
  11. pmc Ultrafiltration in decompensated heart failure with cardiorenal syndrome
    Bradley A Bart
    Hennepin County Medical Center, Minneapolis, Minnesota, USA
    N Engl J Med 367:2296-304. 2012
    ..Little is known about the efficacy and safety of ultrafiltration in patients with acute decompensated heart failure complicated by persistent congestion and worsened renal function...
  12. ncbi request reprint Ultrafiltration versus usual care for hospitalized patients with heart failure: the Relief for Acutely Fluid-Overloaded Patients With Decompensated Congestive Heart Failure (RAPID-CHF) trial
    Bradley A Bart
    Minnesota Heart Failure Consortium, Minneapolis, Minnesota, USA
    J Am Coll Cardiol 46:2043-6. 2005
    ..The purpose of this research was to assess the safety and efficacy of ultrafiltration (UF) in patients admitted with decompensated congestive heart failure (CHF)...
  13. doi request reprint Efficacy and safety of the vasopressin V1A/V2-receptor antagonist conivaptan in acute decompensated heart failure: a dose-ranging pilot study
    Steven R Goldsmith
    Hennepin County Medical Center and University of Minnesota, Minneapolis, Minnesota 55415, USA
    J Card Fail 14:641-7. 2008
    ..This pilot study was designed to evaluate the efficacy and safety of intravenous conivaptan, a dual arginine vasopressin V(1A)/V(2)-receptor antagonist, in treating ADHF...
  14. pmc Obesity and the response to intensified diuretic treatment in decompensated heart failure: a DOSE trial substudy
    Achal Gupta
    Division of Cardiology, University of Utah, Salt Lake City, Utah, USA
    J Card Fail 18:837-44. 2012
    ..Obesity could attenuate diuretic effectiveness in treatment of acute decompensated heart failure (HF)...
  15. doi request reprint Renal effects of conivaptan, furosemide, and the combination in patients with chronic heart failure
    Steven R Goldsmith
    Cardiology Division, Hennepin County Medical Center, Minneapolis, Minnesota 55415, USA
    J Card Fail 17:982-9. 2011
    ..This study investigated the renal and neurohormonal effects of loop diuretics, the mixed vasopressin antagonist conivaptan, and the combination in patients with chronic stable HF...
  16. ncbi request reprint Interactions between the sympathetic nervous system and the RAAS in heart failure
    Steven R Goldsmith
    Hennepin County Medical Center, 701 Park Avenue, Minneapolis, MN 55415, USA
    Curr Heart Fail Rep 1:45-50. 2004
    ....
  17. pmc Cardiorenal rescue study in acute decompensated heart failure: rationale and design of CARRESS-HF, for the Heart Failure Clinical Research Network
    Bradley A Bart
    University of Minnesota, Minneapolis, Minnesota, USA
    J Card Fail 18:176-82. 2012
    ..Ultrafiltration is a potentially attractive alternative to loop diuretics for the management of fluid overload in patients with ADHF and worsening renal function...
  18. doi request reprint Results of the Prospective Minnesota Study of ECHO/TDI in Cardiac Resynchronization Therapy (PROMISE-CRT) study
    Alan J Bank
    Minnesota Heart Failure Consortium, Minneapolis, Minnesota, USA
    J Card Fail 15:401-9. 2009
    ....
  19. ncbi request reprint Congestive heart failure: potential role of arginine vasopressin antagonists in the therapy of heart failure
    Steven R Goldsmith
    Department of Medicine, Hennepin County, Medical Center, Minneapolis, MN 55415, USA
    Congest Heart Fail 8:251-6. 2002
    ..Currently, there are no long-term studies of any type of arginine vasopressin antagonist in human heart failure, but both the theoretical rationale and preclinical data would appear to justify such efforts...
  20. ncbi request reprint Vasopressin antagonists in CHF: ready for clinical trials?
    Steven R Goldsmith
    Cardiovasc Res 54:13-5. 2002